MORGAN STANLEY PLC/CALL/MODERNA/152.5/0.1/20.12.24 | Delayed Börse Stuttgart 13:35:28 04/07/2024 BST | ||
| 0.83 EUR | +2.47% |
|
| Current month | -4.71% | ||
| 1 month | -63.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 04/07/24 | 0.83 | +2.47% |
| 03/07/24 | 0.81 | -3.57% |
| 02/07/24 | 0.84 | +2.44% |
| 01/07/24 | 0.82 | -3.53% |
| 28/06/24 | 0.85 | -8.60% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 01:35 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Morgan Stanley |
| WKN | MB3KM9 |
| ISIN | DE000MB3KM98 |
| Date issued | 10/02/2023 |
| Strike | 152.5 $ |
| Maturity | 20/12/2024 (169 Days) |
| Parity | 10 : 1 |
| Emission price | 6.43 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.74 € |
|---|---|
| Lowest since issue | 0.239 € |
| Spread | 0.07 € |
| Spread % | 7.78% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116
USD
Average target price
145.9
USD
Spread / Average Target
+25.79%
- Stock Market
- Warrants
- Warrant
